[ad_1]
The Federal Public Ministry (MPF) sent this Friday the 11th a letter to the National Complementary Health Agency (ANS) defending the extraordinary incorporation of possible vaccines against covid-19 in the List of Procedures and Events in Health, which provides for all examinations , consultations and treatments covered by private health plans.
The document was signed by attorney Fabiano de Moraes, from the Health Plans Working Group of the III MPF Chamber of Coordination and Review, and addressed to the alternate general director of ANS Rogério Scarabel Barbosa. The piece requests information on the measures and studies that the agency is adopting in relation to the availability of vaccines in private plans.
The Prosecutor’s Office recalls in the letter that, at the beginning of the pandemic, the ANS included diagnostic tests for covid in the list of procedures covered by private plans. In the evaluation of the MPF, the same should be done with vaccines, with a guideline aimed especially at priority and risk groups for covid.
The Federal Public Ministry also expresses that it is concerned about the “lack of definition” of the Ministry of Health in making vaccines available through the National Immunization Program.
Despite minimizing the vaccine, the federal government began to streamline vaccination plans in the country after São Paulo Governor João Doria (PSDB) announced that it will distribute the immunizer in January. The vaccine to be used in the state is Coronavac, produced by China’s Sinovac in association with the Butantan Institute.
One of the measures studied by Bolsonaro is to issue a Provisional Measure to open a loan of R $ 20 billion for the purchase of vaccines. The funds should also be used for the purchase of supplies and for the logistics and communication costs of the vaccination campaign. Initially, the government planned to start vaccination in March, but following Doria’s plans, Health Minister Eduardo Pazuello has been pressured to anticipate the schedule.
In recent days, Pazuello has said that vaccination would be possible until December or January, if any vaccine manufacturer obtains approval from the National Health Surveillance Agency (Anvisa) for the emergency use of the product. As of yet, there is no vaccine licensed by the agency.
